Drug Profile
Research programme: dengue NS3 protein inhbitors - Janssen/Medivir
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica; Medivir AB
- Class
- Mechanism of Action Viral nonstructural protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Dengue in USA
- 14 Feb 2011 Early research in Dengue in USA (unspecified route)